Please ensure Javascript is enabled for purposes of website accessibility

Why Haemonetics Stock Rallied on Friday

By Eric Volkman - May 14, 2021 at 5:56PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One analyst upgrade in particular seemed to bring back the bulls.

What happened

A day after its stock took a 13% bath following the release of fourth-quarter results, Haemonetics (HAE 0.46%) bounced back on Friday. Several analysts tweaked their outlooks on the company, and it closed the day more than 8% higher.

So what

Friday saw five financial services companies tracking Haemonetics stock adjust their views. The analysts at four of those five -- Morgan Stanley, JMP Securities, Needham & Company, Jefferies, and CJS Securities -- all lowered their price targets. Crucially, however, they maintained their recommendations, which were almost all buys or the equivalent thereof (Morgan Stanley maintained at equalweight).

A doctor conferring with one elder and one young man in a healthcare facility.

Image source: Getty Images.

In its earnings release, Haemonetics attributed its revenue and earnings declines to the coronavirus pandemic (many would-be patients postponed certain procedures for fear of being exposed to the virus in a healthcare facility).

Now that the outbreak is receding, the company is optimistic about the future; it proffered guidance indicating that full-year fiscal 2022 revenue will grow by at least 8%, with earnings rising by a minimum of nearly 11%.

Now what

It was the fifth of those adjusted analyses, that from CJS' Larry Solow, which seems to be resonating with Haemonetics-watchers. Surely with an eye on that encouraging company guidance, Solow upped his recommendation from market perform to market outperform.

This feels realistic and achievable. Many of those folks who postponed procedures last year are likely to return soon to the doctor's office or hospital, and Haemonetics' blood and plasma collection systems services should get a boost.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Jefferies Financial Group Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Haemonetics Corporation Stock Quote
Haemonetics Corporation
HAE
$76.23 (0.46%) $0.35
Morgan Stanley Stock Quote
Morgan Stanley
MS
$91.83 (-0.21%) $0.19
Jefferies Financial Group Inc. Stock Quote
Jefferies Financial Group Inc.
JEF
$35.06 (0.16%) $0.06

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
403%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.